Clinical trial · Interventional
Postoperative TACE(Transhepatic Arterial Chemotherapy And Embolization) for Patients With Hepatocellular Carcinoma
A Randomized, Open-label, Phase 3 Trial Evaluating Adjuvant Transarterial Chemoembolization for TNM Stage I and II Hepatocellular Carcinoma Recurrence After Curative Resection
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
1. Hepatocellular carcinoma (HCC) is the most common primary malignancy of liver, representing the third leading cause of cancer-related death worldwide. 2. Its overall dismal prognosis is a result of high incidence rates of metastasis and postoperative recurrence, in particular the intrahepatic recurrence. 3. TACE is the most widely used primary treatment for unresectable HCC. It was also used as the optional treatment for relapsed disease. However, the efficacy of TACE used as adjuvant therapy following hepatectomy remains controversial.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Transcatheter Arterial Chemoembolization | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Observation | Other | — | UNRESOLVED |
| Prophylactic Transcatheter Arterial Chemoembolization | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Adjuvant TACE
- description
- Patients receive adjuvant Transcatheter Arterial Chemoembolization (TACE) following curative resection of HCC.
- interventionNames
- Drug: Prophylactic Transcatheter Arterial Chemoembolization
- type
- ACTIVE_COMPARATOR
- label
- Observation
- description
- Patients do not receive TACE or any other adjuvant therapy following curative resection of HCC.
- interventionNames
- Other: Observation
Primary outcomes (1)
- measure
- RFS(Recurrence free survival)
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Pathological diagnosis of HCC (AJCC stage I or II) * Without recurrence in 1 month postoperation * Must be tolerant to TACE Exclusion Criteria: * With intrahepatic recurrence postoperation * Insufficient liver function * Stage III or IV
References
Publications (0)
Data not yet available